Effect of carboplatin when administered after dacarbazine failure: Clinical benefit of sequential therapy

Merry,Eve; Marples,Maria; Danson,Sarah; Harding,David; Denny,James; Vazquez,Ignacio; Chesshire,Louise; Taylor,Fiona; Fusi,Alberto; Dalgleish,Angus G.

doi:10.3892/mco.2020.2144

December-2020 Volume 13 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

December-2020 Volume 13 Issue 6

Full Size Image

Article

Effect of carboplatin when administered after dacarbazine failure: Clinical benefit of sequential therapy

Authors:
- Eve Merry
- Maria Marples
- Sarah Danson
- David Harding
- James Denny
- Ignacio Vazquez
- Louise Chesshire
- Fiona Taylor
- Alberto Fusi
- Angus G. Dalgleish
View Affiliations / Copyright

Affiliations: Department of Medical Oncology, St. George's Hospital NHS Trust, London SW17 0QT, UK, Institute of Oncology, St. James's University Hospital, Leeds LS9 7TF, UK, Weston Park Cancer Centre, Weston Park Hospital, University of Sheffield, Sheffield S10 2SJ, UK, Academic Unit of Clinical Oncology, The University of Sheffield, Sheffield S10 2TN, UK
Article Number: 73
|
Published online on: September 21, 2020

https://doi.org/10.3892/mco.2020.2144
Expand metrics +

Abstract

Dacarbazine chemotherapy has been the mainstay of melanoma treatment for >30 years. In the early 2000s, carboplatin (with or without other agents, such as paclitaxel) was the most commonly used second‑line therapy in the UK. The aim of the present study was to report a significant response rate to second‑line carboplatin in patients from three UK institutions who had been previously treated and failed to respond to dacarbazine, and investigate whether sequential therapy may be more effective compared with combination therapy. A total of 104 patients were identified, the majority of whom were treated with carboplatin (area under the curve 5‑6) every 3 weeks for a maximum of 6 cycles. A total of 102 patients were evaluable for response, among whom 11 patients had an objective response (1 complete response and 10 partial responses) and 15 had stable disease, giving an overall response rate of 11% and disease control rate of 26%. The median progression‑free survival was 1.8 months (range, 0.2‑36+ months) and the median overall survival was 4.6 months (range, 0.2‑36+ months). Surprisingly, the majority of the patients who benefited from second‑line carboplatin therapy were those with visceral metastases, the survival of whom would not be expected to exceed 6 months after first‑line treatment.

View Figures

View References

1	Mario S: Long-term survival outcomes with new treatments for advanced melanoma: Questions still in need of answers (ASCO post) Available from: https://ascopost.com/issues/october-25-2019/long-term-survival-outcomes-with-new-treatments-for-advanced-melanoma/. Accessed June 30, 2020.
2	Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 17:2745–2751. 1999.PubMed/NCBI View Article : Google Scholar
3	Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, et al: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 18:158–166. 2000.PubMed/NCBI View Article : Google Scholar
4	Lorigan P, Marples M, Harries M, Wagstaff J, Dalgleish AG, Osborne R, Maraveyas A, Nicholson S, Davidson N, Wang Q, et al: Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K: The MELODY study. Br J Dermatol. 170:87–95. 2014.PubMed/NCBI View Article : Google Scholar
5	Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363:711–723. 2010.PubMed/NCBI View Article : Google Scholar
6	Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al: Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 377:1345–1356. 2017.PubMed/NCBI View Article : Google Scholar
7	Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, et al: Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 386:444–451. 2015.PubMed/NCBI View Article : Google Scholar
8	Kong BY, Carlino MS and Menzies AM: Biology and treatment of BRAF mutant metastatic melanoma. Melanoma Manag. 3:33–45. 2016.PubMed/NCBI View Article : Google Scholar
9	Minor DR, Moore D, Kim C, Kashani Sabet M, Venna SS, Wang W, Boasberg P and O'Day S: Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy. Oncologist. 14:995–1002. 2009.PubMed/NCBI View Article : Google Scholar
10	Hauschild A, Larkin J, Ribas A, Dréno B, Flaherty KT, Ascierto PA, Lewis KD, McKenna E, Zhu Q, Mun Y and McArthur GA: Modelled prognostic subgroups for survival and treatment outcomes in BRAF V600-Mutated metastatic melanoma: Pooled analysis of 4 randomized clinical trials. JAMA Oncol. 4:1382–1388. 2018.PubMed/NCBI View Article : Google Scholar
11	Jungnelius U, Ringborg U, Aamdal S, Mattsson J, Stierner U, Ingvar C, Malmström P, Andersson R, Karlsson M, Willman K, et al: Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial. Eur J Cancer. 34:1368–1374. 1998.PubMed/NCBI View Article : Google Scholar
12	Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC and Papadopulos N: Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol. 7:827–835. 1996.PubMed/NCBI View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Effect of carboplatin when administered after dacarbazine failure: Clinical benefit of sequential therapy

This article is mentioned in:

Abstract

Figure 1

Related Articles